Information Provided By:
Fly News Breaks for March 5, 2020
Mar 5, 2020 | 07:03 EDT
Citi analyst Joel Beatty lowered the firm's price target on Madrigal Pharmaceuticals to $155 from $166 and keeps a Buy rating on the shares. The analyst reduced his estimates to reflect the lowering of the estimated annual price of resmetirom to $7,300 from $8,000. However, he believes resmetirom is one of the most promising agents in later-stage development for the treatment of earlier stage nonalcoholic steatohepatitis.
News For MDGL From the Last 2 Days
There are no results for your query MDGL